Ventricular Tachycardia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ventricular Tachycardia – Pipeline Review, H2 2016’, provides an overview of the Ventricular Tachycardia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia

The report reviews pipeline therapeutics for Ventricular Tachycardia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ventricular Tachycardia therapeutics and enlists all their major and minor projects

The report assesses Ventricular Tachycardia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ventricular Tachycardia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ventricular Tachycardia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ventricular Tachycardia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Armetheon Inc

Audentes Therapeutics Inc

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Milestone Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ventricular Tachycardia Overview 6

Therapeutics Development 7

Pipeline Products for Ventricular Tachycardia - Overview 7

Ventricular Tachycardia - Therapeutics under Development by Companies 8

Ventricular Tachycardia - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Ventricular Tachycardia - Products under Development by Companies 11

Ventricular Tachycardia - Companies Involved in Therapeutics Development 12

Armetheon Inc 12

Audentes Therapeutics Inc 13

Gilead Sciences Inc 14

HUYA Bioscience International LLC 15

InCarda Therapeutics Inc 16

Milestone Pharmaceuticals Inc 17

Ventricular Tachycardia - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

aladorian sodium - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AT-307 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

budiodarone - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

etripamil - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

flecainide acetate - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

GS-967 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

HBI-3000 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Ventricular Tachycardia - Dormant Projects 35

Ventricular Tachycardia - Discontinued Products 36

Ventricular Tachycardia - Product Development Milestones 37

Featured News & Press Releases 37

Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias 37

Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia 37

Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND 37

Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 38

Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

List of Tables

Number of Products under Development for Ventricular Tachycardia, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Ventricular Tachycardia – Pipeline by Armetheon Inc, H2 2016 12

Ventricular Tachycardia – Pipeline by Audentes Therapeutics Inc, H2 2016 13

Ventricular Tachycardia – Pipeline by Gilead Sciences Inc, H2 2016 14

Ventricular Tachycardia – Pipeline by HUYA Bioscience International LLC, H2 2016 15

Ventricular Tachycardia – Pipeline by InCarda Therapeutics Inc, H2 2016 16

Ventricular Tachycardia – Pipeline by Milestone Pharmaceuticals Inc, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Ventricular Tachycardia – Dormant Projects, H2 2016 35

Ventricular Tachycardia – Discontinued Products, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for Ventricular Tachycardia, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports